Share this page
Print this page
Email alert
HEMATOLOGIC MALIGNANCIES
PI3 kinase is well established as a central signaling pathway in cancer, playing a prominent role in cancer cell proliferation and survival.
Inhibiting specific isoforms of the PI3 kinase may provide therapeutic effects without broadly inhibiting the PI3 kinase signaling that is critical to the normal function of healthy cells.
Targeting PI3K Delta in B-Cell Malignancies
The delta isoform of PI3K is expressed primarily in leukyocytes, and the primary physiological role is B-cell signaling, development and survival.
PI3K Delta is over expressed in cell lines and primary patient cells of hematologic malignancies. Calistoga Pharmaceuticals has demonstrated in preclinical studies that treatment CAL-101, a PI3K Delta inhibitor, results in cancer cell death. Inhibiting this target provides a novel opportunity to effectively treat patients with hematologic malignancies.
In an ongoing Phase 1 study, CAL-101 has demonstrated impressive single agent activity in patients with indolent non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
CAL-101 is currently under clinical evaluation in patients with hematologic malignancies.
